Last reviewed · How we verify
NCT04443946
Different Anesthesia Maintain Protocol Effect the Outcome of the Patients
Phase 4 trial testing Propofol in Urinary Surgery in 50 participants. Completed in 5 August 2020.
5 August 2020
Quick facts
| Lead sponsor | China International Neuroscience Institution |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 25 June 2020 |
| Primary completion | 5 August 2020 |
| Estimated completion | 5 August 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Propofol (Propofol) — full drug profile →
- 1% Sevoflurane
- 1% Sevoflurane continue
- Sufentanil (SUFENTANIL) — full drug profile →
- 2% Sevoflurane — full drug profile →
- Propofol half — full drug profile →
Conditions studied
- Urinary Surgery — all drugs for Urinary Surgery →
- General Anesthesia — all drugs for General Anesthesia →
Sponsor
China International Neuroscience Institution — full company profile →
Who can join
Adults 18 to 65, any sex, with Urinary Surgery or General Anesthesia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective open-label randomized study, patients were having elective urological surgery scheduled to last longer than 1 h under necessitating general anesthesia.Group-P: (Propofol group): 3 mg kg-1 min-1 propofol was pumped continuously after endotracheal intubation. Group-PAS: (Propofol and after 20 min adding Sevoflurane group): 3 mg kg-1 min-1 propofol were pumped continuously and add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation. Group-PS: (Propofol and Sevoflurane group): 3 mg kg-1 min-1 propofol were continuously pumped after endotracheal intubation, and 1% sevoflurane was inhaled continuously at the same time. Group-S: (Sevoflurane group): 1% sevoflurane continued to maintain anesthesia after endotracheal intubation. Group-PSu: (Propofol and Sufentanil group): 3 mg kg-1 min-1 propofol, 0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04443946
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Propofol
Trials testing the same drug.
- NCT07251101 — Hemodynamic Effects of Remimazolam vs Propofol During Robot-assisted Gynecologic Surgery · NA · not yet recruiting
- NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
- NCT07269808 — Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration · Phase 3 · recruiting
- NCT07460050 — Comparison of Two Sedative Agents in Terms of Controlled Hypotension · NA · not yet recruiting
- NCT07347496 — A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined · Phase 4 · not yet recruiting
Other China International Neuroscience Institution trials
Trials by the same sponsor.
- NCT06946277 — Assessing the Time-Course of Dexmedetomidine-Induced Analgesia Via EEG · Phase 4 · not yet recruiting
- NCT06671327 — Preemptive Analgesia Of Dexmedetomidine Reduces Per-operation Pain · Phase 4 · not yet recruiting
- NCT06662656 — ED50 of Sufentanil for Intraoperative Analgesia · not yet recruiting
- NCT05500703 — Brain Regions and Functional Neuronal Network Characteristics of Dexmedetomidine Analgesia · Phase 4 · completed
- NCT04432675 — Effects of Crystal Solution and Colloid Solution on Mother and Fetus · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04443946 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by China International Neuroscience Institution
- Last refreshed: 14 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04443946.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing